Weekly injections of monoclonal antibodies (mAb) to T-cell regulatory molecules, into animals challenged with a progressively growing epithelial cell tumor 3152-PRO, decreased tumor incidence and caused significantly slower tumor growth, compared with animals given identical treatments of control rat mAb. Some of the mAb showed significant synergy with rIL-2 in the successful therapeutic treatment of 3152-PRO. Furthermore, spleen cells from treated mice generated strong tumor-specific cytotoxic activity. The successful elimination of progressively growing 3152-PRO tumor rendered animals specifically resistant to a secondary challenge of 3152-PRO tumor cells, but not to 2237-PRO or 3256-PRO, two other, noncrossreactive tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3892/ijo.3.3.503 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!